Cover Image
市場調查報告書

經前症候群:開發平台分析

Premenstrual Syndrome - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 200992
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
經前症候群:開發平台分析 Premenstrual Syndrome - Pipeline Review, H2 2015
出版日期: 2015年07月22日 內容資訊: 英文 41 Pages
簡介

所謂經前症候群,是有關女性的月經週期產生的身體的及精神,心情的變動,及乳房的漲感、食慾不振、倦怠感、神經過敏、心情低落等。

本報告以全球經前症候群治療藥的開發平台為主題,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

簡介

  • 調查範圍

經前症候群 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

在企業開發中的產品

開發治療藥的企業

  • Azevan Pharmaceuticals, Inc.
  • DEKK-TEC, Inc.
  • M et P Pharma AG
  • Pherin Pharmaceuticals, Inc.
  • Umecrine Mood AB

治療藥的評估

  • 單劑產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • PH-80PMD
  • progesterone
  • progesterone
  • Small Molecule-1 to Antagonize GABAA Receptor for PMDD
  • Small Molecule-2 to Antagonize GABAA Receptor for PMDD
  • SRX-251
  • UC-1010

最新開發平台趨勢

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6916IDB

Summary

Global Markets Direct's, 'Premenstrual Syndrome - Pipeline Review, H2 2015', provides an overview of the Premenstrual Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premenstrual Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Premenstrual Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Premenstrual Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Premenstrual Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Premenstrual Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Premenstrual Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Premenstrual Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Premenstrual Syndrome - Overview
    • Pipeline Products for Premenstrual Syndrome - Comparative Analysis
  • Premenstrual Syndrome - Therapeutics under Development by Companies
  • Premenstrual Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Premenstrual Syndrome - Products under Development by Companies
  • Premenstrual Syndrome - Companies Involved in Therapeutics Development
    • Azevan Pharmaceuticals, Inc.
    • DEKK-TEC, Inc.
    • M et P Pharma AG
    • Pherin Pharmaceuticals, Inc.
    • Umecrine Mood AB
  • Premenstrual Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • PH-80PMD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • progesterone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • progesterone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-1 to Antagonize GABAA Receptor for PMDD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-2 to Antagonize GABAA Receptor for PMDD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRX-251 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UC-1010 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Premenstrual Syndrome - Recent Pipeline Updates
  • Premenstrual Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)
      • Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder
      • Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood's candidate drug for severe premenstrual symptoms
      • May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Premenstrual Syndrome, H2 2015
  • Number of Products under Development for Premenstrual Syndrome - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Premenstrual Syndrome - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015
  • Premenstrual Syndrome - Pipeline by DEKK-TEC, Inc., H2 2015
  • Premenstrual Syndrome - Pipeline by M et P Pharma AG, H2 2015
  • Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015
  • Premenstrual Syndrome - Pipeline by Umecrine Mood AB, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Premenstrual Syndrome Therapeutics - Recent Pipeline Updates, H2 2015

List of Figures

  • Number of Products under Development for Premenstrual Syndrome, H2 2015
  • Number of Products under Development for Premenstrual Syndrome - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top